Form 4: Beam Therapeutics CFO Sells Shares to Cover Tax Obligations

Beam Therapeutics' CFO, Terry-Ann Burrell, sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• On April 1, 2024, Terry-Ann Burrell, the Chief Financial Officer of Beam Therapeutics Inc., sold 5,446 shares of common stock at a weighted average price of $32.12.
• The sale was executed to cover tax withholding obligations upon the vesting of restricted stock units granted under the company's 2019 Equity Incentive Plan.
• The transactions were carried out according to a pre-arranged Rule 10b5-1 trading plan adopted on May 19, 2023.
• Following the transaction, Burrell directly owns 70,137 shares of Beam Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (share sale for tax obligations) under a pre-arranged trading plan, so the sentiment is neutral.

Industry Context

Insider sales are a common occurrence, especially to cover tax obligations related to equity compensation. The use of a pre-arranged Rule 10b5-1 trading plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Many biotech companies use equity compensation as a significant part of their overall compensation packages.
• Executive share sales for tax purposes are common across the industry, with companies like CRISPR Therapeutics and Editas Medicine seeing similar transactions by their executives.
• Rule 10b5-1 trading plans are widely adopted by executives in publicly traded companies to manage their stock sales in a compliant manner.

Stakeholder Impact

• The sale of shares by the CFO could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the reason for the sale and the existence of a pre-arranged trading plan.

Key Dates